Skip to main content

Month: July 2020

Commercial National Financial Corporation Reports 2nd Quarter 2020 Earnings

ITHACA, Mich., July 29, 2020 (GLOBE NEWSWIRE) — Commercial National Financial Corporation (Pink Sheets: CEFC) today announced second quarter 2020 net income of $1,147,000, or $.29 per share compared to second quarter 2019 net income of $1,123,000, or $.28 per share.  Return on Equity (ROE) was 11.54% for the second quarter of 2020 compared to 12.32% for the second quarter of 2019.For the second quarter of 2020, net interest income increased $348,000, or 9.7% compared to the second quarter of 2019 primarily due to net interest margin improvement as well as from growth in interest-earning assets related to Paycheck Protection Program loans.  Non-interest income increased by $17,000, or 3.3%.  Operating expenses decreased by $100,000, or 3.7% primarily due to lower professional fees, occupancy and equipment expenses.The provision for...

Continue reading

Brink’s Reports Second-Quarter Results

EPS: GAAP $.27 vs. $.25; non-GAAP $.67 vs $.86Strong revenue recovery (excl. G4S acquisition) from 29% decline at April low point to 14% decline in June; organic decline of 21% in April versus 7% decline in JuneReported revenue down 10% vs 2019, down 17% organically, flat in constant currencyNegative currency translation impact of $86 million (9%) on revenue; operating profit impact: GAAP $13 million (25%), non-GAAP $18 million (20%)Operating profit: GAAP ($1 million), (.1%) margin; non-GAAP $73 million, margin 8.9%, 10% constant currencyGAAP net income $13 million; Adjusted EBITDA $125 million (15.2% margin)Variable and fixed cost reductions greater than expectedG4S acquired businesses performing well, synergies on trackManagement provides 2020 and 2021 adjusted EBITDA sensitivity models based on revenue recovery rangesRICHMOND, Va.,...

Continue reading

Radware Announces Second Quarter 2020 Earnings

Second Quarter 2020 Results and Financial HighlightsRevenues of $58.4 millionNon-GAAP EPS of $0.13; GAAP EPS of $0.01Net cash provided by operating activities of $18 millionFirst Six Months 2020 Results and Financial HighlightsRevenues of $118.5 millionNon-GAAP EPS of $0.26; GAAP EPS of $0.07Net cash provided by operating activities of $39 million; net cash provided by operating activities of $63 million for the last twelve monthsTEL AVIV, Israel, July 29, 2020 (GLOBE NEWSWIRE) — Radware® (NASDAQ: RDWR), a leading provider of cyber security and application delivery solutions, today announced its consolidated financial results for the quarter ended June 30, 2020.“We are pleased with the results for the second quarter, despite the unusual COVID-19 related circumstances as our strong business fundamentals continued to provide us with...

Continue reading

Avoiding Dating Disasters: Check Point Research Helps to Mitigate Significant Vulnerabilities in OkCupid’s Website and Mobile App

SAN CARLOS, Calif., July 29, 2020 (GLOBE NEWSWIRE) — Check Point Research, the Threat Intelligence arm of Check Point® Software Technologies Ltd. (NASDAQ: CHKP), a leading provider of cyber security solutions globally, recently identified and helped mitigate several security flaws on OkCupid’s website and mobile app. If exploited, the vulnerabilities would have allowed a hacker to access and steal the private data of OkCupid users, and send messages from their account without users’ knowledge.Launched in 2004, OkCupid is now one of the leading free online dating services globally with over 50 million registered users and used in 110 countries. In 2019, 91 million connections were made via the site annually, with an average of 50,000 dates arranged every week. During the Covid-19 pandemic, OkCupid has seen a 20% increase in conversations....

Continue reading

Stifel Reports Second Quarter 2020 Results

Net revenues of $895.8 million, increased 11.9% with the year-ago quarter, were the Company’s third highest quarterly net revenues.Record Institutional Group net revenues and fixed income brokerage revenues.Net income available to common shareholders of $103.0 million, or $1.39 per diluted common share.Non-GAAP net income available to common shareholders of $115.3 million, or $1.55 per diluted common share.Annualized return on average tangible common shareholders’ equity (1) was 20.7%.Non-GAAP annualized return on average tangible common shareholders’ equity (1) was 23.2%.ST. LOUIS, July 29, 2020 (GLOBE NEWSWIRE) — Stifel Financial Corp. (NYSE: SF) today reported net income available to common shareholders of $103.0 million, or $1.39 per diluted common share on net revenues of $895.8 million for the three months ended June 30, 2020,...

Continue reading

iQSTEL Q2 Revenues Reach a Record $11M with Operating Subsidiaries Q2 2020 Net Income Surpassing $420K

NEW YORK, NY, July 29, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — iQSTEL Inc. (OTC: IQST), a leading-edge 21st Century Enhanced Telecommunications Service Provider, is pleased to provide the latest figures from Q2 2020 for our operating subsidiaries.iQSTEL’s overall revenues for Q2 2020 surpassed the $11M mark and the net income broke past the $420K mark. The company continues on track to reach further record revenues/income figures as well as new acquisitions throughout the rest of 2020.As seen in the included spreadsheet image (full details in the forthcoming Q2 filing), our operating subsidiaries all had positive Net Income:“The tremendous growth we have seen in 2020 continues despite COVID-19’s global economic impact. Further proof that our business model, a combination of corporate growth and acquisitions, is working...

Continue reading

Innate Pharma Announces Publication of EXPLORE COVID-19 Translational Study Findings in Nature

MARSEILLE, France, July 29, 2020 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the publication of a Nature paper entitled, “Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis,” authored by Innate researchers in partnership with scientists from Hôpitaux Universitaires de Marseille AP-HM (La Timone and North Hospitals), Laveran Hospital, Aix Marseille University, the Centre d’Immunologie de Marseille-Luminy (Inserm, CNRS, AMU) and Marseille Immunopole/AP-HM immunoprofiling laboratory at La Timone Hospital. This Marseille-based exploratory research taskforce, named EXPLORE COVID-19, analyzed immune cells in COVID-19 patients at different stages of the disease. The goal of the study was to gain translational insights to...

Continue reading

INNATE PHARMA ANNOUNCES PUBLICATION OF EXPLORE COVID-19 TRANSLATIONAL STUDY FINDINGS IN NATURE

New research suggests targeting C5a-C5aR1 axis could limit severe inflammatory responseInnate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the publication of a Nature paper entitled, “Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis,” authored by Innate researchers in partnership with scientists from Hôpitaux Universitaires de Marseille AP-HM (La Timone and North Hospitals), Laveran Hospital, Aix Marseille University, the Centre d’Immunologie de Marseille-Luminy (Inserm, CNRS, AMU) and Marseille Immunopole/AP-HM immunoprofiling laboratory at La Timone Hospital. This Marseille-based exploratory research taskforce, named EXPLORE COVID-19, analyzed immune cells in COVID-19 patients at different stages of the disease. The goal of the study was to gain...

Continue reading

INNATE PHARMA ANNONCE LA PUBLICATION DANS NATURE DES RESULTATS DE L’ETUDE TRANSLATIONNELLE EXPLORE COVID-19

Les données suggèrent que le ciblage de la voie C5a-C5aR1 pourrait limiter la réponse inflammatoire sévèreInnate Pharma SA (Euronext Paris : IPH – ISIN : FR0010331421 ; Nasdaq : IPHA) (« Innate » ou la « Société ») a annoncé la publication d’un article dans la revue scientifique Nature, intitulé « Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis »[*], écrit par les chercheurs d’Innate en collaboration avec les Hôpitaux Universitaires de Marseille – AP-HM (Hôpital de la Timone et Hôpital Nord), l’Hôpital Laveran, l’Université Aix-Marseille (AMU), le Centre d’Immunologie de Marseille-Luminy (Inserm, CNRS, AMU) ainsi que le laboratoire d’immunoprofiling de Marseille Immunopôle / AP-HM à l’Hôpital de la Timone.Cette task-force de recherche exploratoire marseillaise, baptisée EXPLORE COVID-19, a...

Continue reading

cBrain er valgt som leverandør på den nationale franske rammeaftale

  Fondsbørsmeddelelse nr. 13/2020 cBrain er valgt som leverandør på den nationale franske rammeaftaleKøbenhavn, 29. juli 2020cBrain er kommet på listen over leverandører hos UGAP, Union des Groupements d’Achats Publics. UGAP er en offentlig myndighed under det franske økonomi- og finansministerium, som understøtter offentlige indkøb, herunder bl.a. en rammeaftale for indkøb af software.Det er et vigtigt skridt for cBrain i Frankrig, at selskabet nu er kommet på UGAP’s rammeaftale.cBrain udbyder F2 på rammeaftalen i form af et serviceabonnement, ofte kaldt software-as-a-service. På rammeaftalen udbyder cBrain endvidere de forskellige typer af konsulentydelser, som kan være relevante i forbindelse med anskaffelse og ibrugtagning af F2, herunder konfigurering af standardsoftwaren, undervisning af brugere og support. Konsulentydelser...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.